AR044824A1 - Agonistas del receptor de melanocortina 4 (mc4), composicion farmaceutica y sus usos - Google Patents
Agonistas del receptor de melanocortina 4 (mc4), composicion farmaceutica y sus usosInfo
- Publication number
- AR044824A1 AR044824A1 ARP040102134A ARP040102134A AR044824A1 AR 044824 A1 AR044824 A1 AR 044824A1 AR P040102134 A ARP040102134 A AR P040102134A AR P040102134 A ARP040102134 A AR P040102134A AR 044824 A1 AR044824 A1 AR 044824A1
- Authority
- AR
- Argentina
- Prior art keywords
- tyr
- arg
- ser
- pro
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 abstract 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a agonistas del receptor MC4 y, como tales, son de utilidad en el tratamiento de trastornos que responden a la activación de este receptor, tales como obesidad, diabetes mellitus y disfunción sexual masculina y/o femenina. Reivindicación 1: Un compuesto de la fórmula (1) y sus sales farmacéuticamente aceptables, en el que W es Glu, Gln, Asp, Asn, Ala, Gly, Thr, Ser, Pro, Met, Ile, Val, Arg, His, Tyr, Trp, Phe, Lys, Leu, Cya o está ausente; R1 es -H, -C(O)CH3, -C(O)(CH2)1-4CH3, -C(O)(CH2)1-4NHC(NH)NH2, Tyr-betaArg-, Ac-Tyr-beta-hArg-, gluconoil-Tyr-Arg-, Ac-diaminobutiril-, Ac-diaminopropionil-, N-propionil-, N-butiril-, N-valeril-, N-metil-Tyr-Arg-, N-glutaril-Tyr-Arg-, N-succinil-Tyr-Arg-, R6-SO2-NHC(O)CH2CH2C(O)-, R6-SO2NHC(O)CH2CH2C(O)Arg-, R6-SO2NHCH2CH2CH2C(O)-, (cicloalquil C3-7)carbonilo, fenilsulfonilo, arilsulfonilo bicíclico C8-14, fenil(CH2)qC(O)-, (arilo bicíclico C8-14)(CH2)qC(O)-,como se muestra en los compuesto de fórmula (2) en el que R2 es -H, -NH2, -NHC(O)CH3, -NHC(O)(CH2)1-4CH3, -NH-TyrC(O)CH3, R6SO2NH-, Ac-Cya-NH-, Tyr-NH-, HO-(C6-H5)-CH2CH2C(O)NH-, o CH3-(C6H5)-C(O)CH2CH2C(O)NH-; R3 es alquilo C1-4 lineal o ramificado, NH2-CH2-(CH2)q-, HO-CH2-(CH3)2CHNH(CH2)4-, R6(CH2)q-, R6SO2NH-, Ser, Ile, como se muestra en los restos de fórmulas (3), q es 0, 1, 2 o 3; R6 es un fenilo o un arilo bicíclico C8-14; m es 1 o 2; n es 1, 2, 3 o 4; R9 es (CH2)p o (CH3)2C-; p es 1 o 2; R10 es NH- o está ausente; R7 es un heteroarilo de 5 o 6 miembros o un anillo heteroarilo de 5 o 6 miembros opcionalmente sustituido con R4; R4 es H, alquilo C1-4 lineal o ramificado, fenilo, bencilo o (C6H5)-CH2-O-CH2-; R8 es fenilo, un anillo fenilo opcionalmente sustituido con X o ciclohexilo; X es H, Cl, F, Br, metilo o metoxi; R11 es -C(O) o -CH2; R5 es -NH2, -OH, glicinol, NH2-Pro-Ser-, NH2-Pro-Lys-, HO-Ser-, HO-Pro-Ser-, HO-Lys-, alcohol de -Ser, alcohol de -Ser-Pro, alcohol de -Lys-Pro, HOCH2CH2-O-CH2CH2NH-, NH2-Phe-Arg-, NH2-Glu-, NH2CH2RCH2NH-, RNH-, o RO- donde R es un alquilo C1-4 lineal o ramificado; y L es -S-S o -S-CH2-S-.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47974003P | 2003-06-19 | 2003-06-19 | |
| US55734704P | 2004-03-29 | 2004-03-29 | |
| US57067604P | 2004-05-13 | 2004-05-13 | |
| US57073704P | 2004-05-13 | 2004-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044824A1 true AR044824A1 (es) | 2005-10-05 |
Family
ID=33556652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102134A AR044824A1 (es) | 2003-06-19 | 2004-06-18 | Agonistas del receptor de melanocortina 4 (mc4), composicion farmaceutica y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070105759A1 (es) |
| EP (1) | EP1644023A2 (es) |
| JP (1) | JP2006527773A (es) |
| KR (1) | KR20060014444A (es) |
| AR (1) | AR044824A1 (es) |
| AU (1) | AU2004251616A1 (es) |
| BR (1) | BRPI0410731A (es) |
| CA (1) | CA2530024A1 (es) |
| CR (1) | CR8159A (es) |
| EA (1) | EA200600055A1 (es) |
| EC (1) | ECSP056236A (es) |
| IL (1) | IL171931A0 (es) |
| MX (1) | MXPA05013951A (es) |
| NO (1) | NO20060259L (es) |
| PE (1) | PE20050284A1 (es) |
| TW (1) | TW200514791A (es) |
| WO (1) | WO2005000339A2 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE361294T1 (de) | 2003-08-20 | 2007-05-15 | Lilly Co Eli | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids |
| EP1658273B1 (en) | 2003-08-20 | 2007-01-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| WO2006073772A1 (en) * | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| EP3925614A3 (en) * | 2005-07-08 | 2022-03-23 | Ipsen Pharma | Melanocortin receptor ligands |
| CA2614678A1 (en) * | 2005-07-08 | 2007-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Ligands of melanocortin receptors |
| KR20090047458A (ko) | 2006-08-08 | 2009-05-12 | 사노피-아벤티스 | 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도 |
| CA2689016C (en) | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| TW200848424A (en) * | 2007-06-15 | 2008-12-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2555522T3 (es) | 2007-11-05 | 2016-01-04 | Ipsen Pharma S.A.S. | Uso de melanocortinas para tratar la sensibilidad a la insulina |
| DK2554666T3 (en) | 2008-01-02 | 2015-11-02 | Danisco Us Inc | PROCEDURE FOR OBTAINING ETHANOL WITHOUT glucoamylase USING PSEUDOMONAS saccharophila G4 amylase AND VARIATIONS THEREOF |
| TW201002340A (en) * | 2008-06-09 | 2010-01-16 | Palatin Technologies Inc | Melanocortin receptor-specific peptides for treatment of obesity |
| CA2727317C (en) * | 2008-06-09 | 2015-02-17 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| EP2440572B1 (en) | 2009-06-08 | 2017-04-05 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| NZ596617A (en) * | 2009-06-08 | 2014-04-30 | Palatin Technologies Inc | Melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| MX2012005859A (es) | 2009-11-23 | 2012-12-17 | Palatin Technologies Inc | Peptidos lineales especificos del receptor de melanocortina-1. |
| EP2504352B1 (en) | 2009-11-23 | 2018-11-14 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| SI3539551T1 (sl) | 2011-12-29 | 2022-02-28 | Rhythm Pharmaceuticals, Inc. | Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP2958562B1 (en) | 2013-02-22 | 2025-09-10 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| RU2020120797A (ru) * | 2013-03-15 | 2020-07-02 | Ритм Фармасьютикалз, Инк. | Пептидные композиции |
| JP6538025B2 (ja) * | 2013-03-15 | 2019-07-03 | リズム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AU2016330773A1 (en) | 2015-09-30 | 2018-04-19 | Charité-Universitätsmedizin Berlin | Method of treating melanocortin-4 receptor pathway-associated disorders |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| KR101917854B1 (ko) * | 2017-08-24 | 2018-11-12 | 한국콜마주식회사 | 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물 |
| CN115010793A (zh) * | 2022-06-17 | 2022-09-06 | 中国农业大学 | 玫瑰叶畸形病毒外壳蛋白多克隆抗体的制备方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485039A (en) * | 1982-06-11 | 1984-11-27 | University Patents, Inc. | Synthetic analogues of α-melanotropin |
| US5674839A (en) * | 1987-05-22 | 1997-10-07 | Competitive Technologies, Inc. | Cyclic analogs of alpha-MSH fragments |
| GB9808229D0 (en) * | 1998-04-17 | 1998-06-17 | Quadrant Holdings Cambridge | Melanocortin receptor ligands |
| MXPA01005818A (es) * | 1998-12-09 | 2003-07-21 | Eleanor Rooseveltl Inst | Composicion y metodo para la regulacion del peso del cuerpo y condiciones asociadas. |
| US6716810B1 (en) * | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| GB9827500D0 (en) * | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
| AU763510B2 (en) * | 1999-03-29 | 2003-07-24 | Procter & Gamble Company, The | Melanocortin receptor ligands |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US6659982B2 (en) * | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| HUP0303078A3 (en) * | 2000-08-30 | 2012-02-28 | Hoffmann La Roche | Cyclic peptidies process for their preparation pharmaceutical compositions containing them and their use |
| WO2003006604A2 (en) * | 2001-07-12 | 2003-01-23 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
-
2004
- 2004-06-17 US US10/556,689 patent/US20070105759A1/en not_active Abandoned
- 2004-06-17 JP JP2006517152A patent/JP2006527773A/ja not_active Withdrawn
- 2004-06-17 KR KR1020057024261A patent/KR20060014444A/ko not_active Ceased
- 2004-06-17 WO PCT/US2004/016625 patent/WO2005000339A2/en not_active Ceased
- 2004-06-17 EP EP04753454A patent/EP1644023A2/en not_active Withdrawn
- 2004-06-17 EA EA200600055A patent/EA200600055A1/ru unknown
- 2004-06-17 MX MXPA05013951A patent/MXPA05013951A/es unknown
- 2004-06-17 CA CA002530024A patent/CA2530024A1/en not_active Abandoned
- 2004-06-17 BR BRPI0410731-4A patent/BRPI0410731A/pt not_active Application Discontinuation
- 2004-06-17 AU AU2004251616A patent/AU2004251616A1/en not_active Abandoned
- 2004-06-18 TW TW093117823A patent/TW200514791A/zh unknown
- 2004-06-18 AR ARP040102134A patent/AR044824A1/es unknown
- 2004-06-18 PE PE2004000599A patent/PE20050284A1/es not_active Application Discontinuation
-
2005
- 2005-11-13 IL IL171931A patent/IL171931A0/en unknown
- 2005-12-16 EC EC2005006236A patent/ECSP056236A/es unknown
- 2005-12-16 CR CR8159A patent/CR8159A/es unknown
-
2006
- 2006-01-18 NO NO20060259A patent/NO20060259L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL171931A0 (en) | 2006-04-10 |
| BRPI0410731A (pt) | 2006-06-20 |
| US20070105759A1 (en) | 2007-05-10 |
| ECSP056236A (es) | 2006-04-19 |
| AU2004251616A1 (en) | 2005-01-06 |
| TW200514791A (en) | 2005-05-01 |
| EP1644023A2 (en) | 2006-04-12 |
| MXPA05013951A (es) | 2006-02-24 |
| NO20060259L (no) | 2006-03-14 |
| WO2005000339A2 (en) | 2005-01-06 |
| CR8159A (es) | 2006-02-09 |
| CA2530024A1 (en) | 2005-01-06 |
| JP2006527773A (ja) | 2006-12-07 |
| WO2005000339A8 (en) | 2005-04-21 |
| EA200600055A1 (ru) | 2006-08-25 |
| WO2005000339A3 (en) | 2005-02-03 |
| PE20050284A1 (es) | 2005-05-20 |
| KR20060014444A (ko) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044824A1 (es) | Agonistas del receptor de melanocortina 4 (mc4), composicion farmaceutica y sus usos | |
| JP2003525294A (ja) | Ｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害剤 | |
| ES2326707T3 (es) | Tripeptidos inhibidores de la hepatitis c. | |
| ES2647927T3 (es) | Conjugados enlazadores del fármaco auriestatina | |
| US6653295B2 (en) | Inhibitors of hepatitis C virus NS3 protease | |
| US6727366B2 (en) | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors | |
| CN101466727B (zh) | Hcv/hiv抑制剂及其用途 | |
| AU2008217187A1 (en) | Macrocyclic compounds as HCV NS3 protease inhibitors | |
| ES2258819T3 (es) | Derivados de dolastina 15. | |
| CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
| AR038888A1 (es) | Amidas heterociclicas | |
| ES2572260T3 (es) | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas | |
| GT200900304A (es) | "antagonistas ciclicos de peptido cxcr4" | |
| AR065300A1 (es) | Compuestos quimicos derivados de 1,2-pirazol | |
| BRPI0510231A (pt) | composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo | |
| PE20051061A1 (es) | 5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS | |
| PE20200664A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| AR076880A1 (es) | Inhibidores de proteasa, composiciones farmaceuticas que los contienen y su uso. | |
| CO6260099A2 (es) | Depsipeptidos ciclicos | |
| RU2020120797A (ru) | Пептидные композиции | |
| DE69108738D1 (de) | Nonapeptide als bombesinantagonisten. | |
| AR018915A1 (es) | Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos | |
| AR077476A2 (es) | Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos | |
| CA2487061A1 (en) | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin f2.alpha. receptor | |
| AR047274A1 (es) | Derivados de oxazoltetraciclinas como antibioticos. metodos de obtencion y composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |